Muscular Dystrophy Treatment Using Classical Complement Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a critical need for safe and effective treatments to prevent, reduce the risk of developing, and treat muscular dystrophies, particularly Duchenne muscular dystrophy, Becker muscular dystrophy, Limb-Girdle Muscular Dystrophies, Collagen Type VI-Related Disorders, Congenital Muscular Dystrophies, and Distal Muscular Dystrophies, as current therapies are inadequate.
Innovation Solution
Administering inhibitors of the classical complement pathway, such as C1 complex, C1q, C1s, or C1r inhibitors, including antibodies, peptides, proteins, nucleic acids, or gene editing agents, to target and inhibit the activity of complement proteins in the classical complement pathway, thereby reducing muscle damage and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat muscular dystrophies, then some muscle function preservation may be achieved, but the treatments are inadequate and do not effectively address the underlying disease mechanism
Solution Approach 1:
The patent identifies complement proteins as harmful factors that drive muscle degradation and fibrosis in muscular dystrophies. By targeting and inhibiting these complement proteins, the therapy converts the previously harmful complement activation into a beneficial effect, reducing muscle weakness and fibrosis progression while preserving muscle function.
2Object-affected harmful factors
If complement proteins are inhibited, then muscle damage and fibrosis are reduced, but the mechanism of action requires identification and targeting of specific complement pathway components
Solution Approach 1:
The patent employs complement protein inhibitors that modulate the activity and expression levels of complement proteins (such as C1q, C1r, C1s, C3, C4, C5, C9) in the classical complement pathway. By changing the functional parameters of these complement proteins through inhibition, the therapy reduces muscle damage and fibrosis without requiring complex multi-component intervention systems.
Data Source
AI summary
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating Duchenne muscular dystrophy, Becker muscular dystrophy, Limb-Girdle Muscular Dystrophies (LGMD), Collagen Type VI-Related Disorders, Congenital Muscular Dystrophies (CMD) and Congenital Myopathies, Distal Muscular Dystrophies/Myopathies. The method comprises administering to a subject an inhibitor of the classical complement pathway, such as a C1 complex inhibitor, a C1 complex inhibitor, a C1q inhibitor, a C1s inhibitor, or a C1r inhibitor.